About: Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
Creator	Miura, Kazutoyo Long, Carole Deng, Bingbing Huang, Wei-Chiao Lovell, Jonathan Mabrouk, Moustafa Ortega, Joaquin Seffouh, Amal Wu, Yimin
source	PMC
abstract	BACKGROUND: The Plasmodium falciparum sexual-stage surface proteins Pfs25 and Pfs230 are antigen candidates for a malaria transmission-blocking vaccine (TBV), and have been widely investigated as such. It is not clear whether simultaneously presenting these two antigens in a particulate vaccine would enhance the transmission reducing activity (TRA) of induced antibodies. To assess this, immunization was carried out with liposomes containing synthetic lipid adjuvant monophosphoryl lipid A (MPLA), and cobalt-porphyrin-phospholipid (CoPoP), which rapidly converts recombinant, his-tagged antigens into particles. METHODS: His-tagged, recombinant Pfs25 and Pfs230C1 were mixed with CoPoP liposomes to form a bivalent vaccine. Antigens were fluorescently labelled to infer duplex particleization serum-stability and binding kinetics using fluorescence resonance energy transfer. Mice and rabbits were immunized with individual or duplexed particleized Pfs25 and Pfs230C1, at fixed total antigen doses. The resulting antibody responses were assessed for magnitude and TRA. RESULTS: Pfs230C1 and Pfs25 rapidly bound CoPoP liposomes to form a serum-stable, bivalent particle vaccine. In mice, immunization with 5 ng of total antigen (individual antigen or duplexed) elicited functional antibodies against Pfs25 and Pfs230. Compared to immunization with the individual antigen, Pfs25 antibody production was moderately lower for the bivalent CoPoP vaccine, whereas Pfs230C1 antibody production was not impacted. All antibodies demonstrated at least 92% inhibition in oocyst density at 750 μg/mL purified mouse IgG in the standard membrane feeding assay (SMFA). At lower IgG concentrations, the bivalent vaccine did not improve TRA; antibodies induced by particleized Pfs25 alone showed stronger function in these conditions. In rabbits, immunization with a 20 µg total antigen dose with the duplexed antigens yielded similar antibody production against Pfs25 and Pfs230 compared to immunization with a 20 µg dose of individual antigens. However, no enhanced TRA was observed with duplexing. CONCLUSIONS: Pfs25, Pfs230 or the duplexed combination can readily be prepared as particulate vaccines by mixing CoPoP liposomes with soluble, recombinant antigens. This approach induces potent transmission-reducing antibodies following immunization in mice and rabbits. Immunization with bivalent, particleized, Pfs230 and Pfs25 did not yield antibodies with superior TRA compared to immunization with particleized Pfs25 as a single antigen. Altogether, duplexing antigens is straightforward and effective using CoPoP liposomes, but is likely to be more useful for targeting distinct parasite life stages.
has issue date	2020-08-28(xsd:dateTime)
bibo:doi	10.1186/s12936-020-03368-5
bibo:pmid	32859199
has license	no-cc
sha1sum (hex)	a30be772922ccc03c4650559ec80642d5d38ce4a
schema:url	https://doi.org/10.1186/s12936-020-03368-5
resource representing a document's title	Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
has PubMed Central identifier	PMC7453371
has PubMed identifier	32859199
schema:publication	Malar J
resource representing a document's body	covid:a30be772922ccc03c4650559ec80642d5d38ce4a#body_text
is schema:about of	named entity 'proteins' named entity 'falciparum' named entity 'HAVE' named entity 'INVESTIGATED' named entity 'SURFACE PROTEINS' named entity 'IMMUNIZATION' named entity 'ANTIGENS' named entity 'TAGGED' named entity 'LIPOSOMES' named entity 'assess' named entity 'Plasmodium falciparum' named entity 'TRA' named entity 'recombinant' named entity 'vaccine' named entity 'immunization' named entity 'lipid' named entity 'MPLA' named entity 'his-tagged' named entity 'vaccine' named entity 'antigen' named entity 'immunization' named entity 'surface' named entity 'Liposomes' named entity 'filtrate' named entity 'clinical-stage' named entity 'Plasmodium falciparum' named entity 'IgG' named entity 'mosquito' named entity 'confidence intervals' named entity 'MVA' named entity 'malaria vaccine' named entity 'HIV' named entity 'SMFA' named entity 'antigens' named entity 'SDS-PAGE' named entity 'liposomes' named entity 'human clinical trials' named entity 'gametocytes' named entity 'antibody' named entity 'disulfide bonds' named entity 'TRA' named entity 'pH 9' named entity 'antigen' named entity 'serum' named entity 'antigen' named entity 'antigen' named entity 'vaccine' named entity 'fertilization' named entity 'life stage' named entity 'pH 9' named entity 'oocyst' named entity 'immunization' named entity 'protein' named entity 'immunization' named entity 'mice' named entity 'HIV' named entity 'peptide' named entity 'his-tagged' named entity 'One-way ANOVA' named entity 'immunization' named entity 'life stages' named entity 'IgG' named entity 'antibody response' named entity 'adjuvanted' named entity '8 days' named entity 'kDa' named entity 'MPLA' named entity 'methanol' named entity 'antigens' named entity 'liposomes' named entity 'lymph nodes' named entity 'SMFA' named entity 'immunization'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software